Top of this page
Skip navigation, go straight to the content

Investors UCB equity story

Since 2015, UCB has embarked on a very important change journey:

the Patient Value Strategy

In 2019 we entered the next phase of our Patient Value Strategy:

“Accelerate & Expand” (2019-2021)

 

 
During this phase, we are accelerating our growth potential by further improving our ability to demonstrate differentiation of our medicines, by accelerating our development timelines through new approaches and by improving patients’ access to our key medicines.

The evolving COVID-19 pandemic is profoundly impacting our lives, and places tremendous strain on healthcare systems and society at large. Since the start of the crisis, UCB has taken measures to protect our colleagues around the world, to stand by patients, to help our communities and take our part in the global response to the pandemic. We know that it is our responsibility to help where we can make an impact. Find out what actions UCB has taken here.

"Accelerate & Expand" (2019-2021)

Making significant progress towards this ambitious goal...

Focus on patients

5 core products

     

Briviact  

2 recent launches

Evenity      Nayzilam

Strengthen R&D

5 Phase late stage assets

bimekizumab

zilucoplan

rozanolixizumab

dapirolizumab pegol

Staccato® alprazolam

 

identify & act on opprotunities

3 major acquisitions & many partnerships

Ra Pharma   Engage

Ferring     Handl THerapeutics

     

 
 
 

2019 achievements

  • Evenity® (romosozumab) and Nayzilam® (midazolam) were approved and launched as planned.
  • bimekizumab delivered three positive Phase 3 study results in psoriasis; submission to regulatory bodies should occur mid-2020.
  • UCB started multiple Phase 3 studies: bimekizumab in psoriatic arthritis, axial spondyloarthitis and hidradenitis suppurativa (early 2020), padsevonil in drug resistant epilepsy and rozanolixizumab in generalized myasthenia gravis as well as in immune thrombocytopenia.
  • UCB0107, our anti-Tau antibody, reported positive Phase 1 results and will enter the confirmatory study.

2020 achievements

  • Cimzia® available to Japanese patients living with plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma
  • Broadening the patient population for Vimpat® with approvals in the U.S., Europe and Japan as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures (PGTCS)
  • Promising progress for bimekizumab: 

Phase 3b study BE RADIANT, comparing bimekizumab to secukinumab for the treatment of adults with moderate-to-severe plaque psoriasis met its primary end points.

Filing in the U.S. & EU for the treatment of adults with moderate-to-severe plaque psoriasis

  • Acquisition of Ra Pharma, Engage Therapeutics & Handl Therapeutics
  • Partnerships signed with Ferring Pharmaceuticals, Roche / Genentech, Lacerta Therapeutics, Microsoft
 

Our key medicines

We bring solutions to people living with neurological or immunological diseases.

Serving patients, our key medicines continued their growth in 2019.

Cimzia

Peak sales guidance

 

  • Cimzia® > € 2 billion by 2024  
  • Vimpat® > € 1.5 billion by 2022  
  • Briviact® > € 600 million by 2026
 
Keppra® reached peak sales of € 1.2 billion in 2008.

Vimpat

 

Keppra logo

Neupro

 
 

Our pipeline

In a challenging environment, our pipeline builds the basis of UCB’s sustainable long term growth.

We continued to create value for patients, advancing our pipeline of potential solutions for severe diseases, expanding our capabilities by investing in state-of-the-art scientific platforms and medical advances, and further progress on our digital business transformation journey.

 

5 late stage assets 

  1. Bimekizumab in psoriasis (PsO), psoriatic arthritis (PsA), axial spondyloarthritis (AxSpA) and hidradenitis suppurativa (HS)
  2. Zilucoplan in general Myasthenia Gravis (gMG)
  3. Rozanolixizumab in Immune ThrombocytoPenia (ITP) &  Myasthenia Gravis (MG)
  4. Dapirolizumab pegol in systemic lupus erythematosus (SLE) in partnership with Biogen
  5. Staccato® alprazolam in acute epileptic seizure

Clinical studies index

UCB is committed to sharing information on studies and making study results publicly accessible. You will find below links to the clinical studies (Phase 2-4) of our main R&D projects.

More information about our clinical studies index and our position paper are available here.

April 2021

 

* In partnership with Biogen

Zilucoplan is also being assessed in:

  • COVID-associated ARDS by University of Ghent (Belgium), Medical Research Council (U.K.) & COMMUNITY Trial (U.S.)
  • amyotrophic lateral sclerosis (ALS) by HEALEY ALS Platform Trial

 

 

 

 

Questions?

Contact the IR team and we will do our best to help you!